Trump administration defends Medicare drug price talks in case brought by Novartis
The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.
Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...
Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...
While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...
Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...
That leap forward came at a sky-high price: more than $2 million per dose, making Zolgensma then the costliest one-time treatment ever. How did a drug rooted, like many, in seed money from the U.S ...
Pharmacy benefits managers, or PBMs, are meant to act as a middleman between drug manufacturers and insurance companies to lower drug prices. But some lawmakers have questioned if thats really the ...
The Maryland House of Delegates has voted overwhelmingly to allow a state board to extend its mandate for lowering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback